Pelthos Therapeutics (NYSEAMERICAN:PTHS) Releases Quarterly Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) posted its quarterly earnings results on Thursday. The company reported ($3.09) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $10.91 million for the quarter.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• Pelthos said ZELSUVMI revenue and prescriptions continued to accelerate, with Q1 2026 net product revenue rising to $10.7 million and prescription units up 25% sequentially to 7,884.
• The company highlighted broadening adoption, with unique prescribers increasing to 3,228 and management saying repeat prescribing is trending higher as more physicians continue to write scripts.
• Commercial access remains strong, with Pelthos reporting 59% commercial insurance coverage and 99% Medicaid coverage for ZELSUVMI, supported by a large PBM contract that reduced friction and helped drive utilization.
• Management said it has expanded the sales force from 50 to 64 reps and will add three more territories in June, while planning launches of Xepi in early 2027 and Xeglyze in mid-2027 to leverage the same commercial infrastructure.
• The balance sheet improved after closing a $50 million term debt loan and drawing $30 million, leaving the company with $32 million of cash at quarter-end and management saying it believes it has sufficient runway to execute its plan.

Pelthos Therapeutics Stock Performance

Pelthos Therapeutics stock traded down $0.97 during midday trading on Friday, reaching $26.72. 8,214 shares of the stock were exchanged, compared to its average volume of 22,192. The firm has a fifty day simple moving average of $23.53. The company has a current ratio of 2.05, a quick ratio of 1.15 and a debt-to-equity ratio of 0.81. The stock has a market cap of $89.78 million, a price-to-earnings ratio of -1.29 and a beta of 3.29. Pelthos Therapeutics has a 52 week low of $9.00 and a 52 week high of $54.29.

Institutional Trading of Pelthos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Knott David M Jr increased its holdings in Pelthos Therapeutics by 9.3% during the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after acquiring an additional 1,792 shares during the period. Geode Capital Management LLC grew its stake in Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares in the last quarter. Persistent Asset Partners Ltd grew its stake in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares in the last quarter. Pale Fire Capital SE grew its stake in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after buying an additional 4,819 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Pelthos Therapeutics in the 4th quarter worth approximately $343,000. Institutional investors own 77.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on PTHS shares. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Oppenheimer boosted their price target on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday. Roth Mkm lowered their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.80.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).